Skip to main content

Table 1 Descriptive characteristics among breast cancer patients by molecular subtypes

From: Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes

Molecular subtypes All cases (N = 464)a Luminal A (N = 228)a Luminal B (N = 99)a HER-2 enriched (N = 43)a TNBC (N = 94)a
Mean (SD) / % Mean (SD) / % Mean (SD) / % Mean (SD) / % Mean (SD) / %
Characteristics at study entry
 Age at blood sampling, years 39.5 (14.5) 40.3 (15.2) 36.5 (10.7) 41.2 (15.1) 39.9 (14.7)
 Age at diagnosis, years 57.9 (12.6) 58.8 (12.8) 57.0 (10.3) 59.0 (13.3) 55.9 (13.8)
 Follow-up after diagnosis, years 8.43 (6.93) 9.35 (6.78) 6.43 (5.59) 7.27 (6.83) 8.72 (8.23)
Clinical variablesb
 SBP, mmHg 125 (19.4) 125 (19.5) 123 (15.9) 129 (24.5) 126 (20.3)
 Waist-hip ratio 0.83 (0.07) 0.84 (0.08) 0.81 (0.06) 0.82 (0.05) 0.84 (0.07)
 BMI, kg/m2 23.4 (3.68) 23.3 (3.26) 23.3 (3.50) 23.3 (3.86) 24.1 (4.80)
Reproductive factorsb
 Number of children, number 1.93 (1.39) 1.88 (1.33) 1.63 (1.11) 2.40 (1.96) 2.26 (1.53)
 Age at menarche, years 13.3 (1.39) 13.2 (1.50) 13.4 (1.28) 13.2 (1.09) 13.4 (1.30)
 HRT use, % 30.5 31.5 28.7 28.6 30.5
Serum samplesb
 Total cholesterol, mmol/l 5.82 (1.30) 5.76 (1.22) 5.77 (1.30) 6.03 (1.32) 5.95 (1.46)
 HDL-cholesterol, mmol/l 1.75 (0.40) 1.76 (0.40) 1.72 (0.32) 1.67 (0.38) 1.78 (0.45)
 Triglycerides, mmol/l 1.16 (0.76) 1.11 (0.59) 1.12 (0.53) 1.35 (1.23) 1.28 (1.14)
Lifestyle factorsb
 Moderate physical activity, % 72.5 72.8 75.3 72.7 68.2
 Current smokers, % 40.4 40.4 38.1 48.5 40.0
Tumor characteristics
Tumor size, mm 24.6 (19.5) 21.6 (18.6) 26.1 (17.8) 30.3 (19.1) 29.2 (23.0)
Number of metastatic lymph nodes 2.03 (3.92) 1.46 (3.23) 3.04 (4.66) 2.00 (2.97) 2.43 (4.67)
Stage, % 1.77 (0.81) 1.59 (0.68) 1.92 (0.80) 2.12 (0.96) 1.95 (0.93)
 1 41.7 51.3 31.6 27.9 35.5
 2 39.6 38.9 49.0 30.2 35.5
 3 15.7 8.80 15.3 37.2 22.9
 4 3.00 0.90 4.10 4.70 6.50
Histologic grading, % 1.92 (0.73) 1.55 (0.57) 2.13 (0.68) 2.54 (0.51) 2.49 (0.65)
 1 30.1 48.6 17.8 2.60 8.60
 2 45.8 47.6 53.3 42.1 34.6
 3 24.1 3.80 28.9 55.3 56.8
Estrogen positive, % 64.2 91.2 88.7 0 0
Progesterone positive, % 47.9 71.6 61.3 0 0
HER2 positive, % 16.0 0 34.0 100 0
Ki-67% 18.9 (17.3) 8.43 (4.98) 30.4 (16.1) 27.9 (17.1) 30.5 (22.0)
Treatment
Type of surgery
 Breast conserving surgery 45.6 54.5 45.1 33.0 27.0
 Mastectomy 52.5 44.6 51.6 66.7 70.3
 Othersc 1.90 0.90 3.30 0.30 2.70
Chemotherapy, % 38.2 25.9 52.6 51.5 49.4
Radiation therapy, % 48.6 66.8 67.0 39.4 54.1
Endocrine therapy, % 50.3 55.7 70.1 21.2 24.7
Outcome
 Recurrence, % 17.0 13.2 17.2 30.2 21.0
 Overall mortality, % 27.8 19.7 29.3 39.5 40.4
 Breast cancer mortality, % 14.4 5.27 20.2 27.9 24.5
  1. aNumbers may vary due to missing information
  2. bClinical variables, reproductive factors, serum samples, and lifestyle factors at study entry
  3. cOther types of surgery include primary reconstruction and oncoplastic surgery
  4. Abbreviations: BMI body mass index, HDL high density lipoprotein, HRT hormone replacement therapy, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, n number of cases, SPB systolic blood pressure